|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.20 USD | +0.14% |
|
+1.65% | -81.74% |
| 10/12 | Sarepta Therapeutics' Myotonic Dystrophy Type 1 Trial Data Could Boost Investor Sentiment, Oppenheimer Says | MT |
| 09/12 | Sarepta Offers 'Attractive' Entry Point After Setbacks, Wedbush Says | MT |
| Capitalization | 232.63Cr 199.73Cr 186.8Cr 174.5Cr 321.98Cr 21TCr 350.34Cr 2.17TCr 843.95Cr 9.91TCr 872.96Cr 854.46Cr 36TCr | P/E ratio 2025 * |
-4.06x | P/E ratio 2026 * | 11x |
|---|---|---|---|---|---|
| Enterprise value | 293.21Cr 251.75Cr 235.44Cr 219.95Cr 405.83Cr 26TCr 441.58Cr 2.73TCr 1.06TCr 12TCr 1.1TCr 1.08TCr 46TCr | EV / Sales 2025 * |
1.38x | EV / Sales 2026 * | 1.41x |
| Free-Float |
95.63% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Sarepta Therapeutics, Inc.
| 1 day | +0.14% | ||
| 1 week | +1.65% | ||
| Current month | +4.03% | ||
| 1 month | +28.55% | ||
| 3 months | +28.92% | ||
| 6 months | -43.18% | ||
| Current year | -81.74% |
| 1 week | 21.44 |  | 22.93 |
| 1 month | 15.94 | | 23 |
| Current year | 10.42 | | 129.84 |
| 1 year | 10.42 | | 129.84 |
| 3 years | 10.42 | | 173.25 |
| 5 years | 10.42 | | 181.83 |
| 10 years | 8 | | 181.83 |
| Manager | Title | Age | Since |
|---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 62 | 26/06/2017 |
Ryan Wong
DFI | Director of Finance/CFO | 46 | 16/07/2025 |
Ian Estepan
DFI | Director of Finance/CFO | 49 | 14/12/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
M. Wilsey
CHM | Chairman | 72 | 16/04/2015 |
| Director/Board Member | 86 | 01/06/2010 | |
Richard Barry
BRD | Director/Board Member | 66 | 02/06/2015 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 4.63% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.14% | +1.65% | -82.48% | -81.24% | 232.63Cr | |
| -0.83% | -1.23% | -26.67% | -11.44% | 346.7Cr | |
| -1.76% | -0.71% | +20.22% | - | 39Cr | |
| -1.55% | -2.18% | - | - | 8.3Cr | |
| Average | -1.00% | -0.25% | -29.64% | -46.34% | 156.54Cr | |
| Weighted average by Cap. | -0.54% | -0.09% | -44.75% | -39.47% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 211.88Cr 181.92Cr 170.14Cr 158.94Cr 293.27Cr 19TCr 319.09Cr 1.97TCr 768.68Cr 9.03TCr 795.11Cr 778.26Cr 33TCr | 158.63Cr 136.2Cr 127.38Cr 119Cr 219.56Cr 14TCr 238.9Cr 1.48TCr 575.51Cr 6.76TCr 595.29Cr 582.68Cr 25TCr |
| Net income | -55Cr -47Cr -44Cr -41Cr -76Cr -4.91TCr -82Cr -508.88Cr -198.29Cr -2.33TCr -205.1Cr -200.76Cr -8.55TCr | 25Cr 22Cr 20Cr 19Cr 35Cr 2.28TCr 38Cr 236.44Cr 92Cr 1.08TCr 95Cr 93Cr 3.97TCr |
| Net Debt | 61Cr 52Cr 49Cr 45Cr 84Cr 5.45TCr 91Cr 564.07Cr 219.79Cr 2.58TCr 227.35Cr 222.53Cr 9.47TCr | -8.76Cr -7.52Cr -7.04Cr -6.57Cr -12Cr -787.67Cr -13Cr -82Cr -32Cr -373.36Cr -33Cr -32Cr -1.37TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/25/10 | 22.20 $ | +0.14% | 31,03,524 |
| 09/25/09 | 22.17 $ | +1.42% | 22,23,202 |
| 08/25/08 | 21.86 $ | -1.80% | 38,09,596 |
| 05/25/05 | 22.26 $ | -2.45% | 26,59,310 |
| 04/25/04 | 22.82 $ | +4.49% | 33,95,986 |
Delayed Quote Nasdaq, December 11, 2025 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SRPT Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition